In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Predictors of progression of light-chain cardiac amyloidosis.

Congress : ESC Congress

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Myocardial Disease – Clinical
  • Session type : Moderated Posters
  • FP Number : P5844

Authors : AS Rameeva (Moscow,RU), KV Vedanova (Moscow,RU), VV Rameev (Moscow,RU), AF Safarova (Moscow,RU), IN Bobkova (Moscow,RU), LV Kozlovskaya (Moscow,RU), SV Moiseev (Moscow,RU)


A.S. Rameeva1 , K.V. Vedanova2 , V.V. Rameev3 , A.F. Safarova4 , I.N. Bobkova1 , L.V. Kozlovskaya3 , S.V. Moiseev3 , 1I.M. Sechenov First Moscow State Medical University, Clinic of Nephrology, Internal and Occupational Diseases, Department of Nephrology - Moscow - Russian Federation , 2I.M. Sechenov First Moscow State Medical University - Moscow - Russian Federation , 3I.M. Sechenov First Moscow State Medical University, Clinic of Nephrology, Internal and Occupational Diseases - Moscow - Russian Federation , 4Peoples Friendship University of Russia (PFUR), Department of Internal Medicine Propaedeutics - Moscow - Russian Federation ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 1237

Background: AL-amyloidosis is a rare disease associated with extracellular deposition of the amyloidogenic immunoglobulin light chains (AL). Heart disease is a major determinant of prognosis in patients with AL-amyloidosis.

Objective: To evaluate potential predictors of progression of AL-amyloidosis in patients with heart and renal involvement.

Methods: We followed 55 patients with biopsy-proven AL-amyloidosis (33 male; median age 57 years (51–66)) who underwent electrocardiogram (ECG), standard echocardiography (Echo), pulsed-wave tissue Doppler imaging (TDI). N-terminal pro-brain natriuretic peptide (NT proBNP) was measured in 34 patients. The glomerular filtration rate (GFR) was estimated with the CKD-EPI equation. 29 patients (53%) had clinical manifestations of heart failure (NYHA class I in 7%, class II in 22%, class III in 20%, class IV in 4%). Advanced chronic kidney disease (CKD stage 3–5) with GFR<60ml/min was diagnosed in 22 participants (40%). The median follow-up period was 44 months (range: 8–56 months).

Results: In 24 patients (group 1) there was stable course of disease during follow-up while 31 patients (group 2) showed progression of amyloidosis and died. Patients in group 1 had lower median baseline NT proBNP level (323.7 vs 5822.0ng/L; p=0,003), interventricular septum thickness (1.2 vs 1.5cm; p=0.0005) and left atrium size (3.6 vs. 3.9cm; p=0,03) and higher left ventricular ejection fraction (61 vs 56%; p=0.001). Low QRS voltages on ECG and transmitral diastolic blood flow parameters (E, A, E/A) had no predictive value. TDI parameters associated with unfavorable outcomes included low peak early E' (median: 8 vs 6.0cm/s in groups 1 and 2, respectively; p=0,02) and low peak late A' (10.5 vs 7.25 cm/s; p=0,004) diastolic lateral mitral annular velocities. Patients who showed cardiac amyloidosis progression had high E/E' ratio (6.6 vs 10.4 in groups 1 and 2, respectively; p=0,008) and low systolic S' lateral mitral annular velocity (10.5 vs 7.0cm/s; p=0,004). However, in patients with early chronic kidney disease (CKD stage 1–2) TDI indices (S', E', A') and NT proBNP levels along with standard Echo findings did not affect prognosis.

Conclusions: NT proBNP level, left atrium size, interventricular septum thickness and TDI data (S', E', A', E/E') are strong predictors of unfavorable prognosis in patients with cardiac and renal AL-amyloidosis, provided that GFR is considered in interpreting their clinical signficance. In patients with normal or near-normal renal function (CKD stage 1–2, GFR ≥60 ml/min) the predictive value of standard Echo, TDI and NT proBNP is reduced.

Please login to My ESC

This content may be restricted, please sign in to check your access.

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are